XRCC4 anticorps
XRCC4
Reactivité: Humain, Rat, Souris
WB, IHC, IF/ICC
Hôte: Lapin
Polyclonal
unconjugated
N° du produit ABIN2990121
-
-
Antigène
Voir toutes XRCC4 Anticorps
-
XRCC4
(X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 4 (XRCC4))
-
Reactivité
-
Humain, Rat, Souris
-
Hôte
-
Lapin
-
Clonalité
-
Polyclonal
-
Conjugué
-
Cet anticorp XRCC4 est non-conjugé
-
Application
-
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (fixed cells) (IF/ICC)
-
Purification
-
Affinity purified
-
Immunogène
-
Recombinant protein of human XRCC4.
-
Isotype
-
IgG
-
Top Product
-
Discover our top product XRCC4 Anticorps primaire
-
-
-
Indications d'application
-
Optimal working dilution should be determined by the investigator.
-
Restrictions
-
For Research Use only
-
-
Format
-
Liquid
-
Concentration
-
Lot specific
-
Buffer
-
PBS, pH 7.3, 0.02 % sodium azide, 50 % glycerol.
-
Agent conservateur
-
Sodium azide
-
Précaution d'utilisation
-
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Stock
-
-20 °C
-
Stockage commentaire
-
Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
-
-
Antigène
-
XRCC4
(X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 4 (XRCC4))
-
Autre désignation
-
XRCC4 (XRCC4 Produits)
-
Synonymes
-
anticorps zgc:73312, anticorps MGC81443, anticorps homolog of human DNA ligase iv-binding protein XRCC4, anticorps 2310057B22Rik, anticorps AW413319, anticorps AW545101, anticorps X-ray repair cross complementing 4, anticorps X-ray repair complementing defective repair in Chinese hamster cells 4, anticorps X-ray repair complementing defective repair in Chinese hamster cells 4 L homeolog, anticorps DNA ligase IV-binding protein, anticorps XRCC4, anticorps xrcc4, anticorps xrcc4.L, anticorps Xrcc4
-
Poids moléculaire
-
Calculated MW: 35 kDa/38 kDa
Observed MW: 45 kDa
-
ID gène
-
7518
-
UniProt
-
Q13426
-
Pathways
-
Réparation de l'ADN, Production of Molecular Mediator of Immune Response
-